Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
Johnson and Johnson
Moodys
Merck

Last Updated: August 19, 2022

Investigational Drug Information for Vadadustat


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Vadadustat?

Vadadustat is an investigational drug.

There have been 29 clinical trials for Vadadustat. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2016.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Mitsubishi Tanabe Pharma Corporation, and Otsuka Pharmaceutical Development & Commercialization, Inc.

There are twenty-two US patents protecting this investigational drug and two hundred and thirty-two international patents.

Recent Clinical Trials for Vadadustat
TitleSponsorPhase
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseAkebia TherapeuticsPhase 3
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsAkebia TherapeuticsPhase 3
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsAkebia TherapeuticsPhase 3

See all Vadadustat clinical trials

Clinical Trial Summary for Vadadustat

Top disease conditions for Vadadustat
Top clinical trial sponsors for Vadadustat

See all Vadadustat clinical trials

US Patents for Vadadustat

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Vadadustat See Plans and Pricing Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) See Plans and Pricing
Vadadustat See Plans and Pricing Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Akebia Therapeutics, Inc. (Cambridge, MA) See Plans and Pricing
Vadadustat See Plans and Pricing Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. (New York, NY) See Plans and Pricing
Vadadustat See Plans and Pricing Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Akebia Therapeutics, Inc. (Cambridge, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Vadadustat

Drugname Country Document Number Estimated Expiration Related US Patent
Vadadustat Australia AU2017261372 2036-05-05 See Plans and Pricing
Vadadustat Canada CA3023278 2036-05-05 See Plans and Pricing
Vadadustat China CN107847398 2036-05-05 See Plans and Pricing
Vadadustat European Patent Office EP3452003 2036-05-05 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKinsey
Johnson and Johnson
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.